Drug intelligence / Profile preview

BIIB107

Development stage: Discontinued
Lead developer: Biogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

BIIB107 is a humanized monoclonal antibody developed by Biogen for the treatment of multiple sclerosis. It targets integrin alpha4beta1 (specifically, integrin alpha4beta1), which are essential for leukocyte trafficking into the brain—a key process in the pathology of multiple sclerosis. By antagonizing these integrins, BIIB107 disrupts their interaction with ligands and prevents leukocyte migration into the central nervous system, thereby reducing inflammation associated with MS. The drug was administered subcutaneously and intravenously in clinical trials but has been discontinued after Phase 1 development for multiple sclerosis[1][3][4][6][7].

Other names: BIIB 107BIIB107BIIB-107

Targets

ITGA4 (Integrin alpha-4)α4β1 (Integrin α4β1)

Beyond the preview

Go deeper on BIIB107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIIB107.

Explore the full profile